[1] 孙俊丽,郑有光,陈叶柔,等.左西孟旦治疗老年急性失代偿性心力衰竭的疗效[J].中国老年学杂志,2015,34(20):5770-5771. [2] 马兰,金振一,金壹伍,等.左西孟旦对急性失代偿性心力衰竭患者心率变异性的影响[J].中国循环杂志,2014,29(3):198-200. [3] Shirakabe A,Hata N,Yamamoto M. et al.Immediate administration of Tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure[J].Circ J,2014,78(4):911-921. [4] 隋韶光,孙雷,刘宇飞,等.冻干重组人脑利钠肽治疗急性失代偿性心力衰竭的临床观察[J].中国药房,2016,27(29):4136-4138. [5] 傅炜钢.左西孟旦对老年急性失代偿性心力衰竭患者血流动力学的影响[J].中国老年学杂志,2014,33(19):5376-5378. [6] 汪雁博,傅向华,谷新顺,等.静脉应用重组人脑利钠肽对急性失代偿性心力衰竭患者肾功能的影响[J].中国老年学杂志,2017,37(6):1368-1371. [7] 杨晓慧,王力.左西孟旦对急性失代偿性心力衰竭患者血流动力学的影响[J].中国急救医学,2015,35(z2):59-60. [8] Salah K,Kok WE,Eurlings LW, et al.A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: A European coLlaboration on Acute decompeNsated Heart Failure: éLAN-HF Score[J].Heart,2014,100(2):115-125. [9] 栾晓嵘,李静,牛广红,等.左西孟旦治疗急性失代偿性心力衰竭患者的临床疗效及不良反应观察[J].中国实用护理杂志,2013,29(20):38-41. [10]付文科,孙玉发,郝卫军,等.左西孟旦治疗老年缺血性心肌病所致急性失代偿性心力衰竭的疗效和安全性分析[J].中华老年心脑血管病杂志,2017,19(2):153-155. [11]梁海青,郭牧,张云强,等.重组人脑利钠肽联合硝普钠治疗急性失代偿性心力衰竭的疗效评价[J].中华老年心脑血管病杂志,2015,17(8):801-804. [12]罗苑苑,林新峰.重组人脑利钠肽对急性失代偿性心力衰竭患者心率变异性的影响[J].实用医学杂志,2013,29(2):291-293. [13]王小燕,马富华.重组人脑利钠肽治疗急性失代偿性心力衰竭的临床观察[J].中国药房,2016,27(35):4977-4979. [14]Kobayashi S,Murakami W,Myoren T, et al.A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation[J].Cardiology,2014,127(2):105-113. [15]王凤,解朝永,王红艳,等.重组人脑利钠肽联合左西孟坦治疗急性失代偿性心力衰竭的临床观察[J].中国药房,2016,27(29):4120-4123. [16]Wong YW,Fonarow GC,Mi X, et al.Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: Findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM)[J]. Am Heart J,2013,166(2):349-356.
2019, Vol. 36 
